Isogenica

Activities: Research & Development Pharmaceutical

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  2. CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
  3. ISPE announces 2024 Facility of the Year Awards category winners The awards programme recognises pharmaceutical companies that are the 'best' in the industry for innovation, operations, digitalisation, supply chain and social impact
  4. Tabletability, compactability and compressibility: What’s the difference? To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be...
  5. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

Related Content

Pharmaceutical

Isogenica licenses CIS display tech to Aro Biotherapeutics

The agreement will serve to leverage each companies' strengths in recombinant protein technologies and biopharmaceutical development
Research & Development

Isogenica, Biolauncher and Cresset BD forge alliance

The joint venture aims to rapidly identify small molecule therapeutics to pharma targets
Ingredients

Isogenica and Phylogica collaborate

Isogenica of Cambridge, UK has agreed with Australian biopharmaceutical company Phylogica to use its CIS display technology to optimise the performance of three of Phylogica's lead compounds targeting CD40 ligand (CD40L).
Subscribe now